Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
novartis.com

See what CB Insights has to offer

Investments

49

Portfolio Exits

28

Partners & Customers

10

Service Providers

1

About Novartis

Novartis (NYSE: NVS) is a global healthcare company that provides solutions to address the evolving needs of patients worldwide. Focusing solely on healthcare, Novartis offers a diversified portfolio to meet these needs including medicines, cost-saving generic pharmaceuticals, preventive vaccines, diagnostic tools, and consumer health products.

Novartis Headquarter Location

Forum 1 Novartis Campus

Basel, 4056,

Switzerland

+41 61 324 11 11

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Novartis

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Novartis in 6 Expert Collections, including Digital Therapeutics.

D

Digital Therapeutics

340 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

S

Synthetic Biology

382 items

P

Pharma Startups

11,639 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

R

Rare Diseases

25 items

I

Industrial SynBio

382 items

Synthetic biology focused on replacing industrial and commercial materials.

N

Nanobiotechnology

704 items

These companies apply nanotechnology to clinical medicine. They research or develop highly specific, nanoscale interventions to aid in screening, diagnosis, and treatment of biological systems.

Novartis Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Novartis Rank

Latest Novartis News

07:45 ET Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer

Sep 15, 2021

- Former Genentech CEO Ian Clark will guide Kyverna's vision to transform the treatment of autoimmune diseases through engineered cell therapies - - Seasoned pharmaceutical executive Karen Walker will lead technical development of Kyverna's T-cell therapies - News provided by Share this article Share this article EMERYVILLE, Calif., Sept. 15, 2021 /PRNewswire/ -- Kyverna Therapeutics, Inc., a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Ian Clark as chair of the company's board of directors and the appointment of Karen Walker as Chief Technology Officer (CTO). Ian Clark, chairman of the board, Kyverna Therapeutics Karen Walker, CTO, Kyverna Therapeutics "Kyverna is honored to welcome Ian as chairman of our board of directors. He is among the most respected leaders in our industry, and his accomplishments have transformed the lives of millions of patients," said Dominic Borie, M.D., Ph.D., President and CEO of Kyverna. "Over several decades, Ian led the delivery of more than a dozen new medicines to market, helping patients fighting autoimmune diseases, idiopathic pulmonary fibrosis, and various types of cancer. His stellar background, track record, and passion will be invaluable to Kyverna as we grow our company and aim to deliver on our mission of curing autoimmune diseases." "Developing medicines for patients with life-threatening illnesses is an incredible responsibility, and one I approach with the utmost urgency," said Mr. Clark. "Kyverna's science is aiming to address the most urgent needs of those who suffer from more than 80 autoimmune diseases with suboptimal treatments and no cures. I'm thrilled at the opportunity to work with Kyverna's board and leadership team to help realize the vision for a company that shows such promise in helping patients with few treatment options." Mr. Clark has more than 35 years of experience in the biopharmaceutical industry. During his seven-year tenure as Genentech's top executive, he ranked among the highest-rated CEOs by Glassdoor, was recognized as the Bay Area's most admired CEO by the San Francisco Business Times, and was awarded the Honorable Mentor of the Year award by the Healthcare Businesswoman's Association. Prior to becoming CEO, Mr. Clark served in a number of leadership roles, including Executive Vice President of Commercial Operations and Senior Vice President and General Manager of Biooncology. Before joining Genentech, Mr. Clark held various positions of increasing responsibility at Novartis, Sanofi, Ivax, and Searle, working in the U.S., U.K., Canada, Eastern Europe, and France. Currently, he serves on the boards of several public biopharmaceutical companies, including Takeda, Agios Pharmaceuticals, Guardant Health, Olema Pharmaceuticals, Corvus Pharmaceuticals, and Avrobio. He is also on the BioFulcrum Board of the Gladstone Institutes. Mr. Clark holds a bachelor's degree in biological sciences and an honorary Ph.D. from Southampton University in the U.K. Karen Walker Appointed Chief Technology Officer Ms. Walker has several decades of broad and deep industry experience developing biopharmaceuticals and cell and gene therapy (CGT) products. She brings extensive and pioneering expertise in the product development, manufacturing, and supply of cell-based therapies and associated analytics. "We are delighted to welcome Karen to the Kyverna team and look forward to her leadership as we actively prepare to bring our first cell therapy to patients," said Dr. Borie. "Karen has world-class expertise in the development of recombinant protein products with a particular focus on cell therapy products. She has championed a focus on associated analytics, essential to the appropriate management, characterization, and control of these therapies to realize the promised benefit to patients. Her expertise and passion will help us advance Kyverna's programs into the clinic as we aim to deliver on our mission of bringing cures to patients who are suffering from debilitating autoimmune disorders." Ms. Walker held positions in Technical Development, Regulatory Affairs, and Quality at a number of companies including Roche/Genentech, Seagen (formerly Seattle Genetics), Novartis, Amgen, Bayer, Bristol-Myers Squibb, and several other small to mid-sized biotech companies. She comes to Kyverna from Roche/Genentech where she was Senior Advisor, Cell and Gene Therapy Manufacturing. In this position, she was instrumental in developing and implementing the strategy for CGT manufacturing and controls into the Roche/Genentech organization. "I am thrilled to be joining the Kyverna team to play my part in bringing transformative cell therapy approaches to patients," said Ms. Walker. "Right now, people suffering from a vast number of autoimmune diseases must settle for suboptimal treatments. Kyverna aims to create a new class of T-cell therapies programmed to target and selectively modulate the underlying causes of autoimmunity. It's an incredibly exciting time in history for Kyverna and for the patients who desperately need us." Prior to Roche/Genentech, she was Vice President of Global Quality at Seagen Inc., formerly Seattle Genetics, Inc., where she oversaw and directed the Global Quality Organization in the U.S. and Europe. Previously, Ms. Walker was Vice President and Global Head of Cell and Gene Therapy Technical Development and Manufacturing for Novartis' CGT Unit. There, she led the Chemistry, Manufacturing, and Controls (CMC) teams through the formation of the strategies and execution of those strategies to develop KYMRIAH® (tisagenlecleucel) through the pivotal trial stage and to filing of the first CAR-T Biologics License Application (BLA) in pediatric acute lymphoblastic leukemia (ALL). During her time at Novartis and continuing to the present, Ms. Walker has been a strong and leading voice in the establishment of industry standardization and contributed to influence emerging regulatory guidance in the area of CGT products globally. Ms. Walker holds a bachelor's degree from St. Olaf College. She is a member of numerous pharmaceutical industry trade organizations, including the Alliance for Regenerative Medicines (ARM) Cell Therapy Manufacturing Committee, Deloitte Industry Working Group for Advanced Therapy Medicinal Products (ATMPs), Parenteral Drug Association (PDA), PDA Biologics Advisory Board, where she was vice chair from 2018 to 2020, and the PDA ATMP Working Group. About Kyverna Therapeutics Kyverna Therapeutics, located in the San Francisco East Bay, is a cell therapy company engineering a new class of therapies for serious autoimmune diseases. The Kyverna therapeutic platform combines advanced T cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the root cause of inflammatory diseases. Kyverna's investors include Westlake Village BioPartners, Vida Ventures, and Gilead Sciences. For more information, please visit https://kyvernatx.com . SOURCE Kyverna Therapeutics

Novartis Investments

49 Investments

Novartis has made 49 investments. Their latest investment was in GentiBio as part of their Series A on August 8, 2021.

CBI Logo

Novartis Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/11/2021

Series A

GentiBio

$157M

Yes

Avidity Partners, JDRF T1D Fund, Matrix Capital Management, OrbiMed Advisors, RA Capital Management, and Seattle Children's Research Institute

3

7/14/2021

Series C

Ribon Therapeutics

$65M

Yes

AbbVie Ventures, Avego Healthcare Capital, Bristol-Myers Squibb, Deerfield Management, Euclidean Capital, Google Ventures, Johnson & Johnson Innovation, Monashee Investment Management, Osage University Partners, Peregrine Ventures, Takeda Ventures, The Column Group, and U.S. Venture Partners

3

7/14/2021

Series A

Dopavision

$14.2M

Yes

Ababax Health, Boehringer Ingelheim Venture Fund, and Seventure Partners

2

3/18/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

1/27/2021

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/11/2021

7/14/2021

7/14/2021

3/18/2021

1/27/2021

Round

Series A

Series C

Series A

Series A

Corporate Minority

Company

GentiBio

Ribon Therapeutics

Dopavision

Subscribe to see more

Subscribe to see more

Amount

$157M

$65M

$14.2M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Avidity Partners, JDRF T1D Fund, Matrix Capital Management, OrbiMed Advisors, RA Capital Management, and Seattle Children's Research Institute

AbbVie Ventures, Avego Healthcare Capital, Bristol-Myers Squibb, Deerfield Management, Euclidean Capital, Google Ventures, Johnson & Johnson Innovation, Monashee Investment Management, Osage University Partners, Peregrine Ventures, Takeda Ventures, The Column Group, and U.S. Venture Partners

Ababax Health, Boehringer Ingelheim Venture Fund, and Seventure Partners

Sources

3

3

2

10

10

Novartis Portfolio Exits

28 Portfolio Exits

Novartis has 28 portfolio exits. Their latest portfolio exit was Rani Therapeutics on July 30, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

7/30/2021

IPO

$991

3

7/23/2021

IPO

$991

1

6/22/2021

Acq - Pending

$991

5

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/30/2021

7/23/2021

6/22/2021

00/00/0000

00/00/0000

Exit

IPO

IPO

Acq - Pending

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

1

5

10

10

Novartis Acquisitions

30 Acquisitions

Novartis acquired 30 companies. Their latest acquisition was Cadent Therapeutics on December 17, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

12/17/2020

Series B - III

$991

$55M

Acquired

18

10/29/2020

Seed VC

$991

$0.93M

Acquired

4

4/20/2020

Seed VC

$0.89M

Acquired

6

11/25/2019

PIPE

Subscribe to see more

$991

$99M

Subscribe to see more

10

7/5/2019

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/17/2020

10/29/2020

4/20/2020

11/25/2019

7/5/2019

Investment Stage

Series B - III

Seed VC

Seed VC

PIPE

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$55M

$0.93M

$0.89M

$99M

$99M

Note

Acquired

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

18

4

6

10

10

Novartis Partners & Customers

10 Partners and customers

Novartis has 10 strategic partners and customers. Novartis recently partnered with BeiGene on August 8, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

8/3/2021

Licensor

BeiGene

China

BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey

BeiGene , Ltd. has also entered into a collaboration with Novartis granting Novartis rights to develop , manufacture , and commercialize tislelizumab in North America , Europe , and Japan .

1

8/2/2021

Licensor

Ionis Pharmaceuticals

United States

Novartis : Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

In 2017 , Novartis entered a collaboration agreement with Ionis Pharmaceuticals , Inc. for pelacarsen .

2

6/7/2021

Licensor

BeiGene

China

BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Microsatellite Instability-High (MSI-H) Or Mismatch Repair-Deficient (dMMR) Solid Tumors

In January 2021 , BeiGene , Ltd. and Novartis entered into a collaboration and license agreement granting Novartis rights to develop , manufacture , and commercialize tislelizumab in North America , Europe , and Japan .

11

5/21/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

5/13/2021

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/3/2021

8/2/2021

6/7/2021

5/21/2021

5/13/2021

Type

Licensor

Licensor

Licensor

Licensor

Licensor

Business Partner

BeiGene

Ionis Pharmaceuticals

BeiGene

Country

China

United States

China

Subscribe to see more

Subscribe to see more

News Snippet

BeiGene Announces Plans to Build New Manufacturing and Clinical R&D Center at Princeton West Innovation Park in Hopewell, New Jersey

BeiGene , Ltd. has also entered into a collaboration with Novartis granting Novartis rights to develop , manufacture , and commercialize tislelizumab in North America , Europe , and Japan .

Novartis : Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events

In 2017 , Novartis entered a collaboration agreement with Ionis Pharmaceuticals , Inc. for pelacarsen .

BeiGene Announces Acceptance Of A Supplemental Biologics License Application In China For Tislelizumab In Microsatellite Instability-High (MSI-H) Or Mismatch Repair-Deficient (dMMR) Solid Tumors

In January 2021 , BeiGene , Ltd. and Novartis entered into a collaboration and license agreement granting Novartis rights to develop , manufacture , and commercialize tislelizumab in North America , Europe , and Japan .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

2

11

10

10

Novartis Service Providers

1 Service Provider

Novartis has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Novartis Team

100 Team Members

Novartis has 100 team members, including current Chief Executive Officer, George Gunn.

Name

Work History

Title

Status

Jacob LaPorte

Founder

Current

George Gunn

Chief Executive Officer

Current

Joseph Jimenez

Chief Executive Officer

Current

Jerry Karabelas

Chief Executive Officer

Current

Harry Kirsch

Chief Financial Officer

Current

Name

Jacob LaPorte

George Gunn

Joseph Jimenez

Jerry Karabelas

Harry Kirsch

Work History

Title

Founder

Chief Executive Officer

Chief Executive Officer

Chief Executive Officer

Chief Financial Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.